ckd-702
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 21, 2020 (NCT04667975)
Timeline
Indications
Mechanism of action
EGFR inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05750290 | Phase 2 | Dec 1, 2022 | National Cancer Center, Korea |
| NCT04667975 | Phase 1 | May 21, 2020 | Chong Kun Dang Pharmaceutical, Seoul National University, Sungkyunkwan University, University of Ulsan |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chong Kun Dang Pharmaceutical | For profit | 1 | 1 | 1 | 2020 |
| National Cancer Center, Korea | Government | 1 | 1 | 1 | 2022 |
| Seoul National University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Ulsan | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1